ABSTRACT OBJECTIVES This study sought to investigate the incidence, management, and clinical relevance of atrial fibrillation (AF) during and after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and evaluate outcomes of different antithrombotic strategies.
A trial fibrillation (AF) is a major public health problem because of its increasing prevalence and strong association with cardiovascular morbidity and mortality (1) . For long-term prevention of stroke and systemic embolism, chronic oral anticoagulant therapy (OAC) is recommended for patients with AF at a moderate or high thromboembolic risk. Approximately 5% to 10% of patients undergoing percutaneous coronary intervention (PCI) were reported to have concomitant AF, and longterm OAC was frequently necessary in these patients (2) (3) (4) (5) . Patients undergoing PCI with stent implantation also require dual antiplatelet therapy (DAPT) (aspirin and P2Y 12 antagonist), with the goal of reducing the risk of ischemic complications, including stent thrombosis. However, the efficacy and safety of combining OAC with DAPT (triple therapy) in these patients is a topic of debate and a limited evidenced-based data on the optimal antithrombotic strategy is available (6) . In addition, the introduction of newer antithrombotic therapies and new stent platforms has raised questions on the optimal antithrombotic treatment regimen for PCI patients who also require OAC because of AF (7) .
Until recently, the prevalence and clinical relevance of AF after PCI with drug-eluting stents (DES) in "realworld" clinical settings had not been fully determined and the optimal antithrombotic therapy for such patients is an emerging clinical problem. The purpose of our study was to: 1) determine the prevalence, treatment, and long-term clinical impact of AF in an unrestricted population who underwent PCI with DES in a "real-world" clinical setting; and 2) compare the relative efficacy and safety of the DAPT and triple therapy in patients with AF using a large cohort of PCI patients receiving DES with long-term follow-up data. Infarction criteria (11) . All study endpoints were confirmed on the basis of source documentation from medical records and were adjudicated by an independent group of clinicians who were unaware of patient information.
The dataset for the analysis is a part of the ASAN-PCI (ASAN Percutaneous Coronary Intervention) registry, which is a prospective, single-center, observational study (12, 13) . Baseline and outcome data were prospectively collected by independent research personnel unaware of the study aims and entered into a central database. We systematically reviewed de- In this observational research data analysis, to carefully define the population of interest and to minimize data-dredging processes, we pre-specified study objectives, a hypothesis, and a statistical approach using a statistical analysis plan (16) . Two- Table 1 . Compared to patients without AF, those with AF were older, had a group. There were no differences in angiographic and procedural characteristics between the 2 groups. The status of antithrombotic therapy during the follow-up is summarized in Table 3 . Adherence to aspirin during the follow-up was similar between the 2 groups. At Among patients who underwent PCI with DES, the 6-year rate of primary outcome was significantly higher in patients with AF than in those without AF (22.1% vs. 8.0%, p < 0.001) ( Table 4 , Figure 1 ). The rate of overall and major bleeding was also higher among AF patients than non-AF patients (9.9% vs. 3.7%, p < 0.001; and 4.5% vs. 1.5%, p < 0.001, respectively).
This trend was consistent for other secondary efficacy and safety outcomes. After multivariable adjustment for traditional risk factors and potential confounders, the presence of AF was significantly associated with a higher long-term risk of ischemic and bleeding events. Overall findings were consistent with propensity-score analysis using the inverseprobability-of-treatment weighting (Online Table 1 ).
Among patients with AF, the 6-year rate of primary outcome was similar between the DAPT and triple therapy group (20.1% vs. 23.8%; p ¼ 0.49) ( Table 5 , Figure 2 ). There was a consistent pattern for death or MI. However, the cumulative rate of stroke (in particular, hemorrhagic stroke) and major bleeding was significantly higher in the triple therapy group than in the DAPT group. After multivariable adjustment, the adjusted risk of primary outcome was similar between the 2 antithrombotic groups; however, the adjusted risks of hemorrhagic stroke and major bleeding were significantly higher in the triple therapy group. These findings were almost similar after adjustment of baseline covariates with the inverse-probability-of-treatment weighting (Online Table 2 ).
In addition, we performed stratified analyses according to the different generation of DES (Online Figures 1 and 2 ). Consistent with overall findings, Values are n (%), median (interquartile range), or mean AE SD. *Dual antiplatelet therapy (DAPT) indicates aspirin and clopidogrel. Triple therapy (TT) indicates aspirin, clopidogrel, and warfarin. †Differentiation between persistent and permanent AF was not considered because diagnosis of these was driven by the attending physician's decision to revert to a sinus rhythm (8) . ‡Antiarrhythmic drug indicates use of flecainide or propafenone.
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes, prior stroke/transient ischemic attack; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category; other abbreviations as in Table 1 . (5, 17, 18) . We also observed a higher incidence of TIMI major and nonmajor bleeding in patients with AF, confirming previous findings from the earlier studies (5, 19, 20) . Such findings suggest that AF is one of the highest-risk categories within the broad spectrum of future cardiovascular risks among patients undergoing PCI with DES.
The practice guidelines and expert consensus documents recommend triple therapy for high-risk patients with AF who underwent PCI at discharge (7, 18, 21) . However, our study demonstrated that only approximately 10% were treated with triple therapy and this proportion was relatively lower than that in other ethnic or clinical groups (22) (23) (24) . This disparity Since DES were introduced, aside from several INR ¼ international normalized ratio; other abbreviations as in Tables 1 and 2 . Event rates are shown as Kaplan-Meier estimates, n (%). HRs are for the AF group as compared with the non-AF group. *Models were adjusted for age, sex, the presence or absence of prior HF, the presence or absence of prior stroke history, the presence or absence of peripheral vascular disease, the presence or absence of chronic renal failure, and clinical indication for PCI (stable angina, unstable angina, NSTEMI, or STEMI).
registries of patients with AF, the best available evi- dwpark@amc.seoul.kr.
